HomeAI · summaries
Storia in 2 fonti
Treeline to go public via reverse merger with Standard BioTools
Treeline Biosciences goes public via reverse merger with Standard BioTools, gaining a $900M cash runway through 2029 for its three Phase 1 oncology programs.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Treeline to go public via reverse merger with Standard BioTools
Treeline Biosciences goes public via reverse merger with Standard BioTools, gaining a $900M cash runway through 2029 for its three Phase 1 oncology programs.
- ·
biopharmadive.com
Stealthy startup Treeline plans a reverse merger
Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.